Using BNR's database to explore immune therapy-related biomarkers associated with DDR.
By analyzing the germline mutation status of DDR signaling pathway-related
genes across different cancer types, combined with clinical data from immune therapy
cohorts, ATM is identified as a potential ICI biomarker